DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Solanezumab is an investigational drug.
There have been 10 clinical trials for Solanezumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2010.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and Mild Cognitive Impairment. The leading clinical trial sponsors are Eli Lilly and Company, Hoffmann-La Roche, and Avid Radiopharmaceuticals.
There are thirteen US patents protecting this investigational drug and three hundred and sixty-one international patents.
Recent Clinical Trials for Solanezumab
|A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease||Eli Lilly and Company||Phase 3|
|A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)||Eli Lilly and Company||Phase 1|
|Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss||Alzheimer's Therapeutic Research Institute||Phase 3|
Top disease conditions for Solanezumab
Top clinical trial sponsors for Solanezumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Solanezumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Solanezumab||Start Trial||Cholestosome vesicles for incorporation of molecules into chylomicrons||THERASYN SENSORS, INC. (Eggertsville, NY)||Start Trial|
|Solanezumab||Start Trial||Combination therapies for the treatment of Alzheimer's disease and related disorders||The General Hospital Corporation (Boston, MA)||Start Trial|
|Solanezumab||Start Trial||Methods of administering IgG1 antibodies and methods of suppressing angiogenesis||University of Kentucky Research Foundation (Lexington, KY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|